Is NiceRx a Marqibo coupon provider?
NiceRx is not a Marqibo coupon, Marqibo discount card, or Marqibo copay card provider. We do not offer Marqibo manufacturer coupons, Marqibo discounts, rebates, Marqibo savings cards, trial offers, or free Marqibo samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.
Marqibo patient assistance program
Patient assistance programs are typically sponsored by pharmaceutical companies and provide free or discounted medications to individuals with low income who are uninsured or under-insured and meet the eligibility criteria that vary by program. There are currently no known patient assistance programs for this medication.
How much does Marqibo cost without insurance?
Without insurance, Marqibo costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Marqibo intravenous kit (5 mg/31 mL) will cost around $18,100 for 1 kit.
How much does Marqibo cost with insurance?
The copay for Marqibo will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.
What is Marqibo?
Marqibo is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Acrotech Biopharma LLC. Marqibo is a cancer medication that interferes with the growth of cancer cells and slows their spread in the body. It is classed as a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on the overall response rate.
Marqibo has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.
What doses of Marqibo are available?
Marqibo is prepared on-site from the components in the Kit. After preparation, each single-dose vial of Marqibo (vinCRIStine sulfate LIPOSOME injection) contains 5 mg/31 mL (0.16 mg/mL) vincristine sulfate.
Marqibo is for intravenous use only. Do not administer by any other route. Administer Marqibo at a dose of 2.25 mg/m2 intravenously over 1 hour once every 7 days.
Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection. Verify the drug name and dose prior to preparation and administration to avoid overdosage.
Please see the full prescribing information and always speak with a healthcare professional for medical advice about any changes to your dose so they can monitor and evaluate your condition.
Marqibo active ingredients
The active ingredient of Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate. Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting in altered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus, preventing chromosome segregation, triggering metaphase arrest and inhibiting of mitosis.
Marqibo side effects
The most common side effects of Marqibo in clinical trials (incidence ≥ 30%) include:
- Constipation, diarrhea
- Decreased appetite
- Peripheral neuropathy
- Febrile neutropenia
In rare instances, Marqibo can cause more serious side effects. These can include:
- Intrathecal administration is fatal
- Neurologic toxicity
- Myelosuppression – monitor blood counts prior to each dose
- Neutropenia, thrombocytopenia, or anemia
- Tumor lysis syndrome
- Constipation, bowel obstruction, and/or paralytic ileus
- Severe fatigue
- Hepatic toxicity
- Embryo-fetal toxicity
Your doctor will assess the benefits of using Marqibo against your risk of adverse events. Patients are encouraged to report negative side effects or adverse reactions of Marqibo to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Marqibo drug interactions
Marqibo can interact with other medications. These include:
- Strong CYP3A inhibitors
- Strong CYP3A inducers
- P-Glycoprotein inhibitors and inducers
This list is not exhaustive and other prescription drugs may interact with Marqibo.
You should not use Marqibo if you:
- Are allergic to the active ingredient vinCRIStine sulfate LIPOSOME injection
- Are allergic to any of the other ingredients in Marqibo
- Have Charcot-Marie-Tooth syndrome or other conditions that cause damage to myelin (protective covering of the nerves in your brain and spinal cord)
- Are pregnant or are planning to become pregnant – females of reproductive potential are advised to use effective contraception during treatment and for 6 months after the last dose
Talk to your doctor before using Marqibo if you:
- Are taking any of the medications that could interact with Marqibo
- Have liver disease
- Have myasthenia gravis, ALS (Lou Gehrig’s disease), multiple sclerosis, or muscular dystrophy
- Have a bowel obstruction called paralytic ileus
- Have peripheral vascular disease such as Raynaud’s syndrome
- Are breastfeeding or are planning to breastfeed
Marqibo is the trademark brand name for vinCRIStine sulfate LIPOSOME injection manufactured by Acrotech Biopharma LLC. A generic version of vinCRIStine sulfate LIPOSOME injection is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Marqibo savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.